Back to School: How biopharma can reboot drug development. Access exclusive analysis here

No pain AND no gain

People who need to lose weight want to do so without feeling like they are constantly hungry. Nastech Inc. says that its intranasal version of the natural hormone PYY3-36 induces a feeling of satiety in patients that measurably reduces their calorie intake. Merck & Co. Inc. last week entered into a deal with NSTK to develop the compound, which would add to the pharma company's pipeline of obesity compounds in Phase I and Phase II development.

According to Steven Quay,

Read the full 795 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE